Oral immune regulation toward disease-associated antigens: Results of phase I clinical trials in Crohn's disease and chronic hepatitis

Annals of the New York Academy of Sciences

Volumn 1029, Issue , 2004, Pages 286-298

  Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Antiviral immunity; Crohn's disease; Hepatitis B virus; Immune response; Oral tolerance; Treatment

Indexed keywords

ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VIRUS DNA;

ANTIGEN PRESENTING CELL; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; NATURAL KILLER CELL; SIDE EFFECT; VIRUS LOAD; VIRUS RESISTANCE;

EID: 14544276288     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1309.059     Document Type: Conference Paper

References (40)

1. WEINER, H.L. 2001. Oral tolerance: Immune mechanisms and generation of Th3-type TGF beta secreting regulatory cells. Microbes Infect. 3: 947-954.
2. MCSORLEY, S.J. & P. GARSIDE. 1999. Vaccination by inducing oral tolerance. Immunol. Today 20: 555-560.
3. STROBER, W., B. KELSALL, L. FUSS, et al. 1997. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol. Today 18: 61-64.
4. ILAN, Y. 2002. Immune downregulation leads to upregulation of an anti-viral response: Lesson from the hepatitis B virus. Microbes Infect. 4: 1317-1326.
5. PODOLSKY, D.K. 2002. Inflammatory bowel disease. N. Engl. J. Med. 347: 417-429.
6. STROBER, W. & M.F. NOURISH. 1995. Immunological diseases of the gastrointestinal tract. In Clinical Immunology: Principles and Practice. R.R. Rich et al., Eds.: 1401-1428. C.V. Mosby. St. Louis, MO.
7. MIZOGUCHI, A., E. MIZOGUCHI, C. CHIBA, et al. 1996. Cytokine imbalance and autoantibody production in T cell receptor-α mutant mice with inflammatory bowel disease. J. Exp. Med. 183: 847-856.
8. NEURATH, M.F., I. FUSS, B.L. KELSALL, et al. 1995. Antibodies to IL12 abrogate established experimental colitis in mice. J. Exp. Med. 182: 1281-1290.
9. SANDBORN, W.J. & S.R. TARGAN. 2002. Biologic therapy of inflammatory bowel disease Gastroenterology 122: 1592-1608.
10. NEURATH, M., B.L. KELSALL, D.H. PRESKY, et al. 1996. Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J. Exp. Med. 183: 2605-2616.
11. GALLIAERDE, V., C. DESVIGNES, E. PEYRON & D. KAISERLIAN. 1995. Oral tolerance to haptens: intestinal epithelial cells from 2,4-dinitrochlorobenzene- fed mice inhibit hapten-specific T-cell activation in vitro. Eur. J. Immunol. 25: 1385-1390.
12. ILAN, Y., S. WEKSLER-ZANGEN, S. BEN-HORIN, et al. 2000. Treatment of experimental colitis by oral tolerance induction: A central role for suppressor lymphocytes. Am. J. Gastroenterol. 95: 966-973.
13. DASGUPTA, A., K. RAMASWAMY, J. GIRALDO, et al. 2001. Colon epithelial cellular protein induces oral tolerance in the experimental model of colitis by trinitrobenzene sulfonic acid. J. Lab. Clin. Med. 138: 257-269.
14. DASGUFTA, A., K.V. KESARI, K.K. RAMASWAMY, et al. 2001. Oral administration of unmodified colonic but not small intestinal antigens protects rats from hapten-induced colitis. Clin. Exp. Immunol. 125: 41-47.
15. GOTSMAN, I., A. SHLOMAI, R. ALPER, et al. 2001. Amelioration of immune-mediated experimental colitis: Tolerance induction in the presence of pre-existing immunity and surrogate antigen bystander effect. J. Pharmacol. Exp. Ther. 297: 926-932.
16. SHLOMAI, A., A. TROP, I. GOTSMAN, et al. 2001. Immunemodulation of experimental colitis: The role of NK1.1+ liver lymphocytes and surrogate antigen-bystander effect. J. Pathol. 195: 498-507.
17. KOLKER, O., A. KLEIN, R. ALPER, et al. 2003. Early expression of interferon gamma following oral antigen administration is associated with peripheral tolerance induction. Microbes Infect. 5: 807-813.
18. CRISPE, N. & W.Z. MEHAL. 1996. Strange brew: T cells in the liver. Immun. Today 11: 236-245.
19. GALLERY, M.P., T. KAMEI & W. FLYE. 1989. The effect of portocaval shunt on delayed-hypersensitivity responses following antigen feeding. J. Surg. Res. 46: 391-394.
20. GODFREY, D.J., K.J. HAMMOND, L.D. POULON, et al. 2000. NKT cells: facts, functions and fallacies. Immunol. Today 21: 573-583.
21. TROP, S., D. SAMSONOV, I. GOTSMAN, et al. 1999. Liver-associated lymphocytes expressing NK1.1 are essential for oral tolerance induction in a murine model. Hepatology 29: 746-755.
22. SAMSONOV, D., S. TROP, R. ALPER, et al. 2000. Enhancement of immune tolerance via induction of NK1.1 positive liver-associated-lymphocytes under immunosuppressive conditions in a murine model. J. Hepatol. 32: 812-820.
23. TROP, S. & Y. ILAN. 2002. NK 1.1+ T cell: A two-faced lymphocyte in immune modulation of the IL4/IFNγ paradigm. J. Clin. Immunol. 22: 270-280.
24. TROP, S., A. NAGLER & Y. ILAN. 2003. Role of NK1.1+ and AsGm-1+ cells in oral immune-regulation of experimental colitis. Inflamm. Bowel Dis. 9: 75-86.
25. ISRAELI, E., E. GOLDIN, N. HEMED, et al. 2003. Oral immune rgulation using colitis extracted proteins-A new mode of treatment for Crohn's disease: Results of a phase I clinical trial. Gastroenterology 124: 518A.
26. ILAN, Y., H. SAITO, N.R. THUMMALA & N.R. CHOWDHURY. 1999. Adenovirus-mediated gene therapy of liver diseases. Semin. Liver Dis. 19: 49-59.
27. TAKAHASHI, M., Y. ILAN, K. SENGUPTA, et al. 1996. Induction of tolerance to recombinant adenoviruses by injection into newborn rats: Long-term amelioration of hyperbilirubinemia in Gunn rats. J. Biol. Chem. 271: 26536-26542.
28. ILAN, Y., P. ATTAVAR, M. TAKAHASHI, et al. 1996. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J. Clin. Invest. 98: 2640-2647.
29. ILAN, Y., V.K. JONA, K. SENGUPTA, et al. 1997. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses. Hepatology 26: 949-956.
30. ILAN, Y., G. DROGUETT, N.R. CHOWDHURY, et al. 1997. Insertion of the adenoviral E3 region into a recombinant viral vector prevents anti-viral humoral and cellular immune responses and permits long-term gene expression. Proc. Nat. Acad. Sci. USA 94: 2587-2592.
31. ILAN, Y., R. PRAKASH, A. DAVIDSON, et al. 1997. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J. Clin. Invest. 99: 1098-1106.
32. ILAN, Y., B. SAUTER, N.R. CHOWDHURY, et al. 1998. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenovirus. Hepatology 27: 1368-1376.
33. ILAN, Y. & J.R. CHOWDHURY. 1999. Induction of oral tolerance towards hepatitis B virus: can we eat the disease and live with the virus? Med. Hypotheses 52: 505-509.
34. CHISARI, F.V. & C. FERRARI. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13: 29-45.
35. REHERMANN, B. 2000. Intrahepatic T cells in hepatitis B: viral controls versus liver cell injury. J. Exp. Med. 191: 1263-1268.
36. GUIDOTTI, L.G. & F.V. CHISARI. 2000. Cytokine-mediated control of viral infections. Virology 273: 221-227.
37. KUROSE, K., S.M. AKBAR, K. YAMAMOTO & M. ONJI. 1997. Production of antibody to hepatitis B surface antigen by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells. Immunology 92: 494-500.
38. GOTSMAN, I., R. BEINART, R. ALPER, et al. 2000. Induction of oral tolerance towards hepatitis B envelope antigens in a murine model. Antiviral Res. 48: 17-26.
39. HOOFNAGLE, J.H. & A.M. DI BISCEGLIE. 1997. The treatment of chronic viral hepatitis. N. Eng. J. Med. 325: 347-356.
40. SAFADI, R., E. ISRAELI, O. PAPO, et al. 2003 Treatment of chronic HBV infection via oral immune regulation towards hepatitis B virus proteins. Am. J. Gastroenterol. 98: 2505-2515.